<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094960</url>
  </required_header>
  <id_info>
    <org_study_id>SOR4636CTIL</org_study_id>
    <nct_id>NCT05094960</nct_id>
  </id_info>
  <brief_title>Measurement of Circulating Cell-free DNA (cfDNA) for Diagnosis and Prognosis of Various Diseases and Evaluation of Tissue Damage</brief_title>
  <official_title>Development of a Fast and Sensitive Method for Measurement of Circulating Cell-free DNA (cfDNA) for Diagnosis and Prognosis of Various Diseases and Evaluation of Tissue Damage Following Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the changes in circulating cell-free DNA (cfDNA) levels during&#xD;
      cardiopulmonary bypass (CPB) and to access their association with outcomes compared to&#xD;
      standard scores.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a prospective study, the investigators enrolled seventy-one consecutive patients&#xD;
      undergoing non-emergent coronary artery bypass grafting. Blood was drawn at baseline, after&#xD;
      20 and 40 minutes on CPB, after cross-clamp removal, and 30 minutes after chest closure.&#xD;
      cfDNA was measured in sera by fluorescent method.&#xD;
&#xD;
      The investigators hypothesize that cfDNA measured by will reflect the magnitude of&#xD;
      inflammation induced by CPB. Thus, these measurements could serve for the real-time prognosis&#xD;
      of patients undergoing cardiac surgery. The investigators correlate cFDNA to laboratories and&#xD;
      clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2009</start_date>
  <completion_date type="Actual">July 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 22, 2011</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>8 Years</target_duration>
  <primary_outcome>
    <measure>prolong LOS-length of stay</measure>
    <time_frame>&gt; 18 hours after the surgery</time_frame>
    <description>intensive care unit length of stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>short term - 30day; long term &gt; 1year</time_frame>
    <description>Mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutrophil-NETosis</measure>
    <time_frame>2 hours after the surgery</time_frame>
    <description>Neutrophil extracellular traps (NETs) released from activated neutrophils that undergo NETosis.</description>
  </secondary_outcome>
  <enrollment type="Actual">71</enrollment>
  <condition>Correlation of cFDNA During CPB to Laboratories SIRS Parameters and Clinical Outcomes</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>5 blood samples for each patient during CABG (coronary artery bypass grafting) surgery pre/on/post cardiopulmonary bypass machine</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood test&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        adult (&gt;18yo), undergoing non-emergent first-time CABG.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective coronary artery bypass grafting surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  Non elective surgery&#xD;
&#xD;
          -  other than CABG surgery&#xD;
&#xD;
          -  Redo CABG&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cfDNA-Circulating cell-free DNA</keyword>
  <keyword>CPB-cardiopulmonary bypass</keyword>
  <keyword>SIRS-systemic inflammatory response syndrome</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

